Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child.
about
Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project dataThe varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.Emerging drugs for varicella-zoster virus infections.Viral exanthems: an update.Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccineIn vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zosterHerpes zoster ophthalmicus in an otherwise healthy 2-year-old child.Neurovirulence of varicella and the live attenuated varicella vaccine virus.A Toddler With Rash, Encephalopathy, and Hemolytic Anemia.Pathogenesis and current approaches to control of varicella-zoster virus infections.Molecular studies of the Oka varicella vaccine.Clinical and molecular aspects of the live attenuated Oka varicella vaccine.Herpes zoster ophthalmicus: declining age at presentation.Differentiated neuroblastoma cells provide a highly efficient model for studies of productive varicella-zoster virus infection of neuronal cellsGenotype analysis of ORF 62 identifies varicella-zoster virus infections caused by a vaccine strain in children.A Healthy 2.5-Year-Old Boy With Herpes Zoster Ophthalmicus as Primary Presentation.Drug-induced uveitis.
P2860
Q26863614-0A2C45F8-B5EF-4FC6-99A1-A25CE4D05C53Q33900399-7CEC4730-B34D-4CB6-AC2B-1498D6C93134Q34027426-35ADE4DF-3837-401E-9183-D942991C5422Q34405380-302912FE-EEAB-4F12-93E2-5C18649D6BF0Q34763836-B5100A18-2FA5-42CA-8721-A7D27EE292FDQ35826062-947E588B-CBD3-4AB2-B504-18DF1D8B0753Q35942988-9D5CB738-2541-4C8A-AB3B-AF1348982586Q35979111-5E2AEE41-2B3D-49C2-8D66-BF12067A0DC3Q36164992-28DD3CC8-EB0D-4FF5-B968-05BBC818D3DEQ36377382-D9836E12-E202-4ECD-867C-1710C5BBC209Q37263293-F90B1064-C31C-4AFA-8DE6-F8E9228F6B7BQ37932527-FE866A35-4E7C-4CB5-943D-86DB56251647Q38200971-8F5DCE4B-29C6-42D5-AA98-79085E70CA52Q38547930-EA2080EE-06FE-481D-97E1-12C7555448C4Q39532127-24F35CA8-0741-438F-B325-42C9C941532AQ40330700-7510539D-ED36-48A4-A38A-781656056149Q50958717-8E3DB3F0-7512-4B5B-88AF-7430EABF065CQ51023399-767A2B13-60CB-4A89-B783-3FD1941580DA
P2860
Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Vaccine-associated herpes zost ...... s in an immunocompetent child.
@en
Vaccine-associated herpes zost ...... s in an immunocompetent child.
@nl
type
label
Vaccine-associated herpes zost ...... s in an immunocompetent child.
@en
Vaccine-associated herpes zost ...... s in an immunocompetent child.
@nl
prefLabel
Vaccine-associated herpes zost ...... s in an immunocompetent child.
@en
Vaccine-associated herpes zost ...... s in an immunocompetent child.
@nl
P2093
P356
P1433
P1476
Vaccine-associated herpes zost ...... s in an immunocompetent child.
@en
P2093
Giorgos Chouliaras
Maria Theodoridou
Mark Quinlivan
Vana Spoulou
P304
P356
10.1542/PEDS.2009-2633
P407
P577
2010-03-01T00:00:00Z